U.S. Boulder Study: 11th Subject Treated; 12th Enrolled; IRB Approves Protocol Amendment

On August 15, 2014, the 11th subject was treated in our ongoing study of MDMA-assisted psychotherapy for PTSD for 23 subjects with PTSD from sexual assault, violent crime, war, natural disasters, or any other cause, taking place in Boulder, Colorado. The 12th subject was enrolled on August 5.

All funds contributed to our Legalizing Psychedelic Therapy campaign above $50,000 will pay for costs associated with this study, including over 200 experimental and non-drug preparatory and integrative psychotherapy sessions; customizing the treatment room; storing and preparing the MDMA; training therapists; and gathering, monitoring, and analyzing the data. On August 18, an amendment to the study was submitted to the Institutional Review Board, and was approved on August 28. The amendment adds greater variability in dosing options for subjects’ unblinded sessions, giving subjects randomly assigned to the 100mg condition for their first two sessions the option of requesting either a 100mg or 125mg dose for their third experimental session. “The first two treatments with 100mg felt like I helped the medicine help me,” reported one participant. “With the 125mg, the medicine was right there to help and hold me. It held me and supported me doing my work.”